Primary hyperoxaluria is a rare, genetic disorder that results from an excessive endogenous synthesis of oxalate. Glyoxylate reductase (GR) is a key enzyme in this biosynthetic pathway, converting glyoxylate, the main precursor of oxalate, to glycolate and thereby limiting its conversion to oxalate. The long term goals of this project are to develop an in depth understanding of the pathways associated with GR activity and glyoxylate and oxalate synthesis, to determine the metabolic consequences of an absence of GR activity, and to identify therapeutic strategies that limit oxalate synthesis when the activity is absent. To assist with these goals we have developed a cell line with reduced GR activity and have obtained a knockout (KO) species of mouse lacking GR activity. This proposal has three specific aims.
The first aim i s to determine the phenotype of the KO mouse, measuring anion concentrations in blood, urine and tissues using ion chromatography coupled to mass detection (IC/MS).
The second aim i s designed to test the hypothesis that inhibiting hydroxyproline oxidase (HPOX) will be an effective therapeutic strategy for decreasing the increased oxalate synthesis associated with GR deficiency. To establish proof of principle, RNA interference will be utilized to inhibit HPOX activity and decrease oxalate synthesis. The KO mouse will be used as a model for these studies. In the third specific aim, the functional role of GR in red blood cells will be examined. These cells have a simplified metabolism in comparison to other cells and preliminary data indicate that these cells contain glycolate, glyoxylate and oxalate, as well as GR activity. It is hypothesized that GR functions to limit oxalate production and to synthesize glycolate, a potential substrate for phosphoglycolate synthesis. These hypotheses will be tested in cells from KO mice and human cells incubated with glycolate and glyoxylate. These studies will increase our understanding of the metabolism associated with oxalate synthesis and will potentially identify novel therapeutic strategies to decrease oxalate synthesis in primary hyperoxaluria. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK054468-07
Application #
7316284
Study Section
Urologic and Kidney Development and Genitourinary Diseases Study Section (UKGD)
Program Officer
Rasooly, Rebekah S
Project Start
1999-05-01
Project End
2011-06-30
Budget Start
2007-09-01
Budget End
2008-06-30
Support Year
7
Fiscal Year
2007
Total Cost
$294,175
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Surgery
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Patel, Mikita; Yarlagadda, Vidhush; Adedoyin, Oreoluwa et al. (2018) Oxalate induces mitochondrial dysfunction and disrupts redox homeostasis in a human monocyte derived cell line. Redox Biol 15:207-215
Fargue, Sonia; Milliner, Dawn S; Knight, John et al. (2018) Hydroxyproline Metabolism and Oxalate Synthesis in Primary Hyperoxaluria. J Am Soc Nephrol 29:1615-1623
Liebow, Abigail; Li, Xingsheng; Racie, Timothy et al. (2017) An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. J Am Soc Nephrol 28:494-503
Wood, Kyle D; Holmes, Ross P; Knight, John (2016) RNA interference in the treatment of renal stone disease: Current status and future potentials. Int J Surg 36:713-716
Chacko, Balu K; Zhi, Degui; Darley-Usmar, Victor M et al. (2016) The Bioenergetic Health Index is a sensitive measure of oxidative stress in human monocytes. Redox Biol 8:43-50
Williams, Jennifer; Holmes, Ross P; Assimos, Dean G et al. (2016) Monocyte Mitochondrial Function in Calcium Oxalate Stone Formers. Urology 93:224.e1-6
Fargue, Sonia; Knight, John; Holmes, Ross P et al. (2016) Effects of alanine:glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell-based cytotoxicity assay. Biochim Biophys Acta 1862:1055-62
Li, Xingsheng; Knight, John; Fargue, Sonia et al. (2016) Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase. Biochim Biophys Acta 1862:233-9
Fu, Y; Rope, R; Fargue, S et al. (2015) A mutation creating an out-of-frame alternative translation initiation site in the GRHPR 5'UTR causing primary hyperoxaluria type II. Clin Genet 88:494-8
Li, Xingsheng; Knight, John; Todd Lowther, W et al. (2015) Hydroxyproline metabolism in a mouse model of Primary Hyperoxaluria Type 3. Biochim Biophys Acta 1852:2700-5

Showing the most recent 10 out of 23 publications